Oruka Therapeutics to Unveil Phase 2a Trial Results for ORKA-001 in Plaque Psoriasis Treatment

Menlo Park, CA – April 27, 2026 – Oruka Therapeutics, Inc. (Nasdaq: ORKA) is set to disclose pivotal Week 16 data from its ongoing EVERLAST-A Phase 2a trial for ORKA-001, a novel biologic aimed at treating moderate-to-severe plaque psoriasis. The results, scheduled for release at 8:00 a.m. ET today, could mark a significant milestone in the company’s mission to redefine chronic skin disease treatment with long-lasting, high-efficacy therapies.

Why This Trial Matters

Plaque psoriasis affects over 8 million Americans and 125 million people worldwide, according to the National Psoriasis Foundation. Current treatments often require frequent dosing—ranging from weekly to monthly injections—which can burden patients and reduce adherence. Oruka’s approach focuses on biologics designed to achieve complete disease clearance with dosing as infrequent as once or twice a year, potentially transforming patient outcomes.

What to Expect from the EVERLAST-A Trial Results

The EVERLAST-A trial is evaluating ORKA-001’s safety and efficacy in patients with moderate-to-severe plaque psoriasis. Key metrics likely to be highlighted in today’s announcement include:

• Primary Endpoint: The proportion of patients achieving a 90% or greater reduction in the Psoriasis Area and Severity Index (PASI 90) by Week 16.
• Secondary Endpoints: Rates of complete skin clearance (PASI 100), improvements in quality of life measures (e.g., Dermatology Life Quality Index), and safety profiles.
• Dosing Frequency: Insights into whether ORKA-001’s mechanism of action supports extended dosing intervals, aligning with Oruka’s goal of reducing treatment burden.

How ORKA-001 Stands Out

ORKA-001 is part of Oruka’s proprietary portfolio of antibodies engineered by Paragon Therapeutics. Unlike existing biologics that target cytokines like IL-17 or IL-23, ORKA-001 is designed to modulate upstream pathways, potentially addressing the root causes of plaque psoriasis. If successful, this could position ORKA-001 as a best-in-class therapy with:

• Higher rates of complete clearance compared to current standards.
• Reduced dosing frequency, improving patient compliance.
• A safety profile comparable to or better than existing biologics.

How to Access the Results

Oruka Therapeutics will host a live webcast at 8:00 a.m. ET today to discuss the EVERLAST-A trial data. Investors, analysts, and healthcare professionals can join via:

• Webcast Link: Oruka Therapeutics Investor Relations
• Replay Availability: A recording of the call will be accessible on the same page shortly after the live event.

Oruka’s Broader Vision

Founded with the mission to “offer patients suffering from chronic skin diseases the greatest possible freedom from their condition,” Oruka Therapeutics is advancing a pipeline of biologics targeting dermatologic and inflammatory diseases. Beyond plaque psoriasis, the company is exploring applications for ORKA-001 and other candidates in conditions like atopic dermatitis and hidradenitis suppurativa.

Alan Lada, Oruka’s Investor Relations contact, emphasized the significance of the EVERLAST-A data in a recent statement: “This trial represents a critical step in validating our approach to chronic skin disease treatment. We’re excited to share these results with the medical and investment communities.”

Market and Investor Implications

The plaque psoriasis market is projected to reach $37.2 billion by 2027, driven by increasing disease prevalence and demand for more effective, convenient therapies. Oruka’s stock (ORKA) has seen volatility in recent months as investors await clinical milestones. Today’s data release could serve as a catalyst for the company’s valuation, depending on the strength of the results.

Analysts will be closely watching for:

• Comparative Efficacy: How ORKA-001 stacks up against competitors like AbbVie’s Skyrizi or Janssen’s Tremfya.
• Safety Signals: Any adverse events that could impact regulatory pathways.
• Regulatory Pathway: Insights into potential Phase 3 trial designs or accelerated approval opportunities.

Key Takeaways for Investors and Patients

• Game-Changing Potential: ORKA-001 could redefine plaque psoriasis treatment if it delivers on its promise of high efficacy with infrequent dosing.
• Short-Term Catalyst: Today’s data release may significantly impact Oruka’s stock performance and investor sentiment.
• Long-Term Pipeline: Success in EVERLAST-A could accelerate Oruka’s broader pipeline, including programs in atopic dermatitis and other inflammatory diseases.
• Patient-Centric Approach: Oruka’s focus on reducing treatment burden aligns with growing demand for therapies that improve quality of life.

What’s Next for Oruka Therapeutics?

Following the EVERLAST-A results, Oruka is expected to outline its Phase 3 trial strategy and potential partnerships with larger pharmaceutical companies. The company has also hinted at additional data readouts for other pipeline candidates later in 2026.

For patients and healthcare providers, today’s announcement could signal a shift toward more durable, patient-friendly treatments for chronic skin diseases. For investors, it’s a pivotal moment that could shape Oruka’s trajectory in the competitive biotech landscape.

FAQs

What is ORKA-001?

ORKA-001 is a novel biologic developed by Oruka Therapeutics to treat moderate-to-severe plaque psoriasis. It is designed to target core mechanisms underlying the disease, potentially enabling high rates of complete clearance with less frequent dosing.

How does ORKA-001 differ from existing treatments?

Most current biologics for plaque psoriasis target specific cytokines (e.g., IL-17, IL-23). ORKA-001 aims to modulate upstream pathways, which could lead to more durable responses and reduced dosing frequency.

When will ORKA-001 be available to patients?

If the EVERLAST-A trial is successful, Oruka will likely proceed to Phase 3 trials, which could grab several years. Regulatory approval and commercial launch would follow, contingent on trial outcomes and regulatory reviews.

How can I participate in future Oruka Therapeutics trials?

Interested patients can visit Oruka’s clinical trials page for information on ongoing and upcoming studies.

Where can I uncover more information about Oruka Therapeutics?

For the latest updates, visit Oruka Therapeutics’ official website or follow the company on LinkedIn.